You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1914 Results
Guidelines and Advice
Status: Current
ID: GL 4-18
Version: N/A
Sep 2020
Statistical Reports
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bevacizumab,
oxaliplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023
Guidelines and Advice
Status: Archived
ID: GL-7-A-2016-3
Apr 2017
Statistical Reports
Aug 2020
Guidelines and Advice
Status: Archived
ID: 4-10
Aug 2013
Last updated: April 30, 2019 The following information identifies errors and corrections in the Ontario Cancer Statistics 2018 report and supporting...
Mar 2019
Guidelines and Advice
Status: Current
Mar 2019
Guidelines and Advice
Status: In-Review
ID: FA 2
Mar 2015
Guidelines and Advice
Status: Archived
ID: 17-5
Jul 2016

Pages